9.00-11.00 Session 1: Local production in developing countries

Organizer: Warren Kaplan, Boston University
Chair: Ilyse Zable, IFC

The purpose of the session is to identify opportunities for the World Bank and the IFC to support efficient and sustainable production of quality drugs. The session will try to identify our knowledge on pharmaceutical production in developing countries, as well as the existing gaps. It will also address the complexities of pharmaceutical production in order to assess what type of production can be carried out efficiently in developing countries and try to set a research agenda on local production issues.

• Warren Kaplan, Boston University. Historical perspective on local production of pharmaceuticals in developing countries. What do we really know about local production from a global perspective?
• Bill Haddad, BIOGENERICS. Nature, stages and characteristics of the process of producing a drug; Practical approaches in supporting technology transfer for drug production in developing countries
• Michael Van Vleck, Phyto-Riker. Practical issues in creating and maintaining local pharmaceutical production in Ghana.
• Enrique Cavallone, ASILFA (Chilean Manufacturers Association). Technical issues in pharmaceutical generics production.

Organizer: Juan Rovira, The World Bank
Chair: F.M. Scherer, Princeton University

The purpose of the session is to review the theoretical framework of differential pricing, as well as the evidence on its application and effects in actual cases. The session will also review normative approaches and proposals for equity pricing as a way to improving access to drugs in developing countries.

• Carsten Fink, The World Bank. Theory and evidence on differential pricing
• Juan Rovira, The World Bank. Equity pricing: concept and proposals
• Patricia Danzon, University of Pennsylvania

1.30-5.00 Session 3: Compensation and Compulsory Licenses: implementing the Doha Declaration and advancing the UN Millennium Development Goals

Organizer: Jamie Love, Consumer Project on Technology.

The session will consist of two panels, both addressing the same question: How does one reconcile the Doha Declaration on TRIPS to ensure access to medicines for all with the TRIPS obligations on compensation to patent owners when non-voluntary use of a patent is authorized?

1.30-3.00 Panel 1

Chair: Ruldolf V. Van Puymbroeck, Lead Counsil, The World Bank.

• F.M. Scherer, Princeton University. The Economics of Compuslory Drug Patent Licensing.
• Jerome Reichman, Duke University. Sharing information from his two recent papers on compulsory licensing for UNCTAD on the US and Canadian experiences.
• Martin Adelman, George Washington University. Perspectives of the research based pharmaceutical industry.

Chair: Yolanda Tayler, Senior Procurement Specialist, The World Bank

• William Jack, Georgetown University and Jenny Lanjouw, Brookings Institution. A Ramsey Pricing Model for setting affordable royalties.
• Aidan Hollis, University of Calgary. Setting compensation for developed and developing countries.
• James Love, Consumer Project on Technology. Affordable royalties in developing countries.

Due to space constraints, please confirm attendance to Akosua Dakwa, adakwa@worldbank.org, phone 202 458 2283.

The sessions will be video-recorded and made available for public access at B-SPAN, the World Bank's web casting station on development issue.